Combinations for treating cancer comprising an anti-EGFR antibody and VEGFR inhibitors.

摘要

Use of a fully human anti-EGFR antibody in combination with a VEGFR inhibitor, wherein the anti-EGFR antibody is panitumumab fully human and VEGFR inhibitor is N- (2,3-dihydro-3,3-dimethyl-1H indol-6-yl) -2 - [(4-pyridinylmethyl) amino] -3-pyridinecarboxamide, for the manufacture of a medicament for the control or treatment of small cell lung cancer, colon carcinoma and squamous cell carcinoma in a subject .